Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ACAB) is a biopharmaceutical company that emerged from a SPAC combination, operating in the healthcare and life sciences sector with a focus on antibody engineering and therapeutic discovery. The company filed an 8-K with the Securities and Exchange Commission on April 8, 2025, signaling a material corporate development following its transition from blank-check vehicle to operating registrant. Abpro Corporation, the underlying operating entity, develops antibody-based candidates targeting oncology and immunology indications. The filing, carrying accession number 0001213900-25-029934, reflects the company's continued reporting obligations as a public entity. Sign up for full data, filings, and sponsor history on SpacDesk.